MedTrace Logo

Anti-HIV Medications and Structured Treatment Interruptions for People Recently Infected With HIV

NCT00084032 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2012-10-29

No results posted yet for this study

Summary

People recently infected with HIV who are treated with anti-HIV medications may develop strong immune system responses to HIV and may be able to control the virus without continuing to take these medications. The purpose of this study is to see if giving anti-HIV medications to people soon after they have been infected with HIV can help them control HIV. The study will also see if the immune system can control the amount of HIV virus in the blood (viral load) even after a person has stopped taking the medications. The study will evaluate three different schedules of stopping and starting anti-HIV medications to see which schedule is best able to boost a patient's immune system to control HIV viral load.

Hypothesis: Combination therapy started in primary HIV infection, in conjunction with structured treatment interruptions, will result in greater control of viremia off treatment than induction therapy alone.

Conditions

  • HIV Infections

Interventions

BEHAVIORAL

Structured treatment interruption

Treatment interruption schedule is dependent on the Arm in which participants are enrolled in Step 2

DRUG

Antiretroviral regimen

Participants will take any combination of FDA-approved ARV medications prescribed by their physician

Sponsors & Collaborators

  • National Institute of Allergy and Infectious Diseases (NIAID)

    lead NIH

Principal Investigators

  • Eric Rosenberg, MD · Massachusetts General Hospital

  • Don Smith, MB, ChB, MD · University of New South Wales, Australia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00084032 on ClinicalTrials.gov